(Q38255323)

1 September 2017

1 reference

title

Interstitial lung disease in connective tissue disease--mechanisms and management (English)

1 reference

interstitial lung disease

1 September 2017

1 reference

1 reference

Athol U Wells

1

1 reference

1 September 2017

Christopher P Denton

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

30 September 2014

1 reference

Nature Reviews Rheumatology

1 September 2017

1 reference

1 September 2017

10

1 reference

1 September 2017

12

1 reference

1 September 2017

728-739

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.149

1 September 2017

0 references

cites work

Interstitial lung disease in connective tissue disorders

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Increased epithelial permeability in pulmonary fibrosis in relation to disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II Transforming growth factor-{beta} receptor (T{beta}RII{delta}k).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Fibroblast-specific Expression of a Kinase-deficient Type II Transforming Growth Factor β (TGFβ) Receptor Leads to Paradoxical Activation of TGFβ Signaling Pathways with Fibrosis in Transgenic Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Prediction of pulmonary complications and long-term survival in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Autoantibodies as predictive tools in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

A polymorphism in the CTGF promoter region associated with systemic sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Influence of the IL6 gene in susceptibility to systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Significance of connective tissue diseases features in pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Distinct phenotypes in mixed connective tissue disease: subgroups and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Connective tissue disease-associated interstitial lung disease: a call for clarification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Clinicopathological features of pure mica pneumoconiosis associated with Sjögren syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjögren's syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Polymyositis-dermatomyositis-associated interstitial lung disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Interstitial lung disease in the patient who has connective tissue disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Significance of connective tissue disease features in idiopathic interstitial pneumonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Autoimmune-featured interstitial lung disease: a distinct entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Acute exacerbations of idiopathic pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Pulmonary function tests in connective tissue disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Primary Sjögren's syndrome and associated lung disease: CT findings in 50 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

High-resolution chest CT in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Interstitial lung disease in systemic sclerosis: a simple staging system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Combined pulmonary fibrosis and emphysema in connective tissue disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Severe restrictive lung disease in systemic sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Severe organ involvement in systemic sclerosis with diffuse scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Cyclophosphamide versus placebo in scleroderma lung disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Interstitial lung disease in polymyositis and dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

High-dose acetylcysteine in idiopathic pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Rituximab treatment of the anti-synthetase syndrome: a retrospective case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.149

Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria

31 March 2020

1 reference

12 December 2020

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis

1 reference

12 December 2020

Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine.

1 reference

12 December 2020

A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis

1 reference

12 December 2020

Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis

1 reference

12 December 2020

Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement

1 reference

12 December 2020

Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2014.149

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference